Skip to main content

Cognitive Decline

1
Pipeline Programs
12
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
MemantinePhase 21 trial
Active Trials
NCT04033419Completed55Est. Apr 2022
Neurosteer
NeurosteerIsrael - Tel Aviv
2 programs
Neurosteer Aurora systemN/A1 trial
Neurosteer EEG recorderN/A1 trial
Active Trials
NCT04386902Completed60Est. Jul 2020
NCT05528445Completed77Est. Aug 2023
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Cohort Study of Risk Factors for Postoperative Cognitive DeclineN/A1 trial
Active Trials
NCT03676738Completed125Est. May 2022
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Dalcroze Eurhythmics ProgramN/A1 trial
Active Trials
NCT03384602CompletedEst. Nov 2022
BioMarin Pharmaceutical
1 program
laronidaseN/A
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
laronidaseN/A1 trial
Active Trials
NCT00852358Completed9Est. Apr 2015
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
FINGER 2.0 multidomain lifestyle-based interventionPHASE_21 trial
Active Trials
NCT05109169Recruiting600Est. Jun 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Merck & Co.FINGER 2.0 multidomain lifestyle-based intervention
Human BioSciencesMemantine
NeurosteerNeurosteer EEG recorder
NeurosteerNeurosteer Aurora system
Oregon TherapeuticsCohort Study of Risk Factors for Postoperative Cognitive Decline
City TherapeuticsDalcroze Eurhythmics Program
Angeles Therapeuticslaronidase

Clinical Trials (7)

Total enrollment: 926 patients across 7 trials

NCT05109169Merck & Co.FINGER 2.0 multidomain lifestyle-based intervention

METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia

Start: Jan 2023Est. completion: Jun 2027600 patients
Phase 2Recruiting
NCT04033419Human BioSciencesMemantine

Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

Start: Sep 2019Est. completion: Apr 202255 patients
Phase 2Completed
NCT05528445NeurosteerNeurosteer EEG recorder

Evaluation of Cognitive State in Seniors Using Neurosteer EEG System

Start: May 2022Est. completion: Aug 202377 patients
N/ACompleted
NCT04386902NeurosteerNeurosteer Aurora system

Evaluation of Cognitive State Using Neurosteer EEG System

Start: Sep 2019Est. completion: Jul 202060 patients
N/ACompleted
NCT03676738Oregon TherapeuticsCohort Study of Risk Factors for Postoperative Cognitive Decline

Cohort Study of Risk Factors for Postoperative Cognitive Decline

Start: Mar 2018Est. completion: May 2022125 patients
N/ACompleted
NCT03384602City TherapeuticsDalcroze Eurhythmics Program

MOVE for Your MIND

Start: Dec 2017Est. completion: Nov 2022
N/ACompleted
NCT00852358Angeles Therapeuticslaronidase

A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

Start: Jun 2009Est. completion: Apr 20159 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 926 patients
12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.